تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $2.4B | $2.3B | $2.2B | $1.8B | $1.6B | $1.4B | $988M | $968M | $854M | $452M | $191M | $37M | $25M | $31M | $47M | $290M | $185M | $152M | $118M | $113M | $99M |
| سود ناخالص | $2.4B | $2.2B | $2.1B | $1.8B | $1.6B | $1.4B | $951M | $935M | $827M | $437M | $185M | $33M | $23M | $30M | $47M | $290M | $185M | $152M | $118M | $113M | $98M |
| حاشیه سود ناخالص % | 96.4% | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | 96.3% | 96.6% | 96.9% | 96.7% | 96.6% | 89.5% | 91.9% | 96.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 99.2% |
| سود عملیاتی (EBIT) | $971M | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | ($28M) | ($121M) | ($224M) | ($201M) | ($122M) | $90M | ($91M) | ($122M) | ($179M) | ($157M) | ($127M) |
| حاشیه سود عملیاتی % | 39.8% | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | -14.7% | -326.7% | -893.9% | -640.5% | -258.0% | 30.9% | -49.4% | -80.3% | -152.1% | -138.4% | -128.5% |
| سود خالص | $861M | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | ($70M) | ($170M) | ($269M) | ($245M) | ($148M) | $76M | ($92M) | ($135M) | ($163M) | ($86M) | ($101M) |
| حاشیه سود خالص % | 35.3% | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | -36.7% | -456.6% | -1069.4% | -781.0% | -311.2% | 26.1% | -49.9% | -89.1% | -138.2% | -76.1% | -102.9% |
| EBITDA | — | $922M | $719M | $283M | $222M | $300M | $119M | $378M | $452M | $167M | ($22M) | ($120M) | ($213M) | ($196M) | ($115M) | $100M | ($73M) | ($116M) | ($156M) | ($157M) | ($110M) |
| سود هر سهم (EPS) | $3.17 | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | $-0.28 | $-0.81 | $-1.38 | $-1.33 | $-0.92 | $0.58 | $-0.85 | $-1.26 | $-1.54 | $-0.87 | $-1.17 |
| سهام منتشرشده (میلیون) | — | 282M | 296M | 321M | 325M | 322M | 318M | 315M | 313M | 312M | 251M | 209M | 194M | 184M | 160M | 130M | 109M | 107M | 105M | 99M | 87M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی EXEL در دسترس است. /companies/us/EXEL
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms